SILO PHARMA, INC. Increase (Decrease) in Receivables
SILO PHARMA, INC. (SILO) reported Increase (Decrease) in Receivables of $3.59 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-25.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInReceivables · last filed 2024-08-13
- SILO PHARMA, INC. increase (decrease) in receivables for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- SILO PHARMA, INC. increase (decrease) in receivables for the quarter ending 2023-09-30 was $1.21K, a 0.00% change year-over-year.
- SILO PHARMA, INC. increase (decrease) in receivables for the quarter ending 2023-06-30 was $1.20K, a 0.08% increase year-over-year.
- SILO PHARMA, INC. increase (decrease) in receivables for the quarter ending 2023-03-31 was $1.18K, a 0.08% decline year-over-year.
- SILO PHARMA, INC. increase (decrease) in receivables for fiscal 2023 was $3.59K, a 25.21% decline from fiscal 2022.
- SILO PHARMA, INC. increase (decrease) in receivables for fiscal 2022 was $4.80K, a 296.69% increase from fiscal 2021.
- SILO PHARMA, INC. increase (decrease) in receivables for fiscal 2021 was $1.21K.
| Period end | Increase (Decrease) in Receivables 3 month | Increase (Decrease) in Receivables 6 month | Increase (Decrease) in Receivables 9 month | Increase (Decrease) in Receivables 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $1.21K derived: sum of 2 quarters · filed 2024-03-25 | $2.41K derived: sum of 3 quarters · filed 2024-08-13 | $3.59K 10-K · filed 2024-03-25 |
| 2023-09-30 | $1.21K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $2.41K derived: sum of 2 quarters · filed 2024-08-13 | $3.59K 10-Q · filed 2023-11-13 | $4.80K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-06-30 | $1.20K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $2.38K 10-Q · filed 2024-08-13 | $3.59K derived: sum of 3 quarters · filed 2024-08-13 | $4.80K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $1.18K 10-Q · filed 2024-05-13 | $2.39K derived: sum of 2 quarters · filed 2024-05-13 | $3.60K derived: sum of 3 quarters · filed 2024-05-13 | $4.80K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $1.21K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $2.42K derived: sum of 2 quarters · filed 2024-03-25 | $3.62K derived: sum of 3 quarters · filed 2024-03-25 | $4.80K 10-K · filed 2024-03-25 |
| 2022-09-30 | $1.21K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $2.41K derived: sum of 2 quarters · filed 2023-11-13 | $3.59K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $1.20K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $2.38K 10-Q · filed 2023-08-11 | ||
| 2022-03-31 | $1.18K 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | $1.21K 10-K · filed 2023-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |